IMB Dx is a precision oncology company focused on developing solutions for safe & accurate cancer diagnosis & monitoring. We created AlphaLiquid®, a minimally-invasive liquid biopsy method which requires only a single blood draw to detect cancer and monitor its progress. With AlphaLiquid®, we offer a comprehensive genomic profile of the tumor and matching therapies as well as clinical trial information. Since we began our research in 2014, our goal has remained the same: to make cancer diagnosis accessible and affordable to as many cancer patients as possible. For more information, please visit us at www.imbdx.com/eng/ or contact us at [email protected].
我们正在追踪 IMBdx 的市场扩张
IMBdx 的国际扩张与竞争对手的对比情况
IMBdx你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 IMBdx你 | 0 | 0 | — | 0 | 0 |
IMBdx 첨단바이오 융합인재(AI전문가) 모집
查看职位Seoul, South Korea · 3周前
Global BD Manager
查看职位Seoul, South Korea · 8个月前
Global Business Development Manager
查看职位Seoul, South Korea · 8个月前
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
多家韩国公司公布2025年第二季度财务业绩，包括Kiwoom证券、SOOP、GS建设等。多家公司宣布投资、合同和公司行动。
IMBdx的首次公开募股超额认购，认购保证金达10.7万亿韩元，吸引465,671名认购者，竞争比率为2654.2比1。
Teragen Bio 被选为 PAVE 项目的执行机构，开发个性化抗癌疫苗。与 NeoVax-K 联盟合作，目标将预测准确率提高到 90% 以上。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 IMBdx 的业务、市场和增长信号的快速解答。
